Seneca BioPharma is a biopharmaceutical company developing novel treatments for nervous system diseases of high unmet medical need. Our lead asset, NSI-189, is a new chemical entity in Phase 2 clinical development for major depressive disorder (MDD). Our lead stem cell asset, NSI-566, is a spinal cord-derived neural stem cell line being tested in stroke, ALS, chronic spinal cord injury (cSCI) and Amyotrophic Lateral Sclerosis (ALS). These product candidates are based on the company's proprietary neural stem cell technology.
20271 Goldenrod Lane
Germantown, MD 20876
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
Biological Products, Except Diagnostic Substances (2836)